Endometriosis : involvement of stem cells and clinical impact by Andersson Di Claudio, Karin
Thesis for doctoral degree (Ph.D.)
2016
Endometriosis - involvement of stem 
cells and clinical impact
Karin Andersson Di Claudio
Th
esis fo
r d
o
cto
ral d
egree (Ph
.D
.)  2016
K
arin
 A
n
d
ersso
n
 D
i C
laud
io
Endom
etriosis - involvem
ent of stem
 cells and clinical im
pact
From the Department of Women’s and Childrens Health 
Karolinska Institutet, Stockholm, Sweden 
ENDOMETRIOSIS -INVOLVEMENT OF STEM CELLS AND 
CLINICAL IMPACT 
 
Karin Andersson Di Claudio 
 
Stockholm 2016 
 
From the Department of Women’s and Childrens Health 
Karolinska Institutet, Stockholm, Sweden 
ENDOMETRIOSIS -INVOLVEMENT OF STEM CELLS AND 
CLINICAL IMPACT 
 
Karin Andersson Di Claudio 
 
Stockholm 2016 
 
  
All previously published papers were reproduced with permission from the publisher. 
Published by Karolinska Institutet. 
Printed by E-print 
Cover image: “Studio per la testa di Leda” Leonardo da Vinci (Firenze 1505). 
© Karin Andersson Di Claudio, 2016 
ISBN 978-91-7676-224-0  
 
 
All previously published papers were reproduced with permission from the publisher. 
Published by Karolinska Institutet. 
Printed by E-print 
Cover image: “Studio per la testa di Leda” Leonardo da Vinci (Firenze 1505). 
© Karin Andersson Di Claudio, 2016 
ISBN 978-91-7676-224-0  
 ENDOMETRIOSIS – INVOLVEMENT OF STEM CELLS 
AND CLINICAL IMPACT 
 
 
THESIS FOR DOCTORAL DEGREE (Ph.D.) 
By 
Karin Andersson Di Claudio 
Principal Supervisor: 
Kristina Gemzell-Danielsson,  
Professor, MD, PhD 
Karolinska Institutet 
Department of Women’s and Children’s Health 
Division of Obstetrics and Gynecology 
 
Co-supervisor(s): 
Lalit Parameswaran Grace Kumar, PhD 
Karolinska Institutet 
Department of Women’s and Children’s Health 
 
 
Opponent: 
Dharani Hapangama, MD, PhD 
Reader in Gyneacology 
University of Liverpool  
Institute of Translational Medicine 
 
Examination Board: 
Matts Olovsson, Professor, MD, PhD 
Uppsala University 
Department of Women's and Children's Health 
 
Kenny Rodriguez-Wallberg, MD, PhD 
Karolinska Institutet 
Department of Oncology and Pathology 
 
Mats Brännström, Professor, MD, PhD 
Sahlgrenska Academy/University of Gothenburg 
Department of Obstetrics and Gynecology 
 
 
 
 
ENDOMETRIOSIS – INVOLVEMENT OF STEM CELLS 
AND CLINICAL IMPACT 
 
 
THESIS FOR DOCTORAL DEGREE (Ph.D.) 
By 
Karin Andersson Di Claudio 
Principal Supervisor: 
Kristina Gemzell-Danielsson,  
Professor, MD, PhD 
Karolinska Institutet 
Department of Women’s and Children’s Health 
Division of Obstetrics and Gynecology 
 
Co-supervisor(s): 
Lalit Parameswaran Grace Kumar, PhD 
Karolinska Institutet 
Department of Women’s and Children’s Health 
 
 
Opponent: 
Dharani Hapangama, MD, PhD 
Reader in Gyneacology 
University of Liverpool  
Institute of Translational Medicine 
 
Examination Board: 
Matts Olovsson, Professor, MD, PhD 
Uppsala University 
Department of Women's and Children's Health 
 
Kenny Rodriguez-Wallberg, MD, PhD 
Karolinska Institutet 
Department of Oncology and Pathology 
 
Mats Brännström, Professor, MD, PhD 
Sahlgrenska Academy/University of Gothenburg 
Department of Obstetrics and Gynecology 
 
 
 

 ”There are only two ways to live your life. One is as though nothing is a miracle.  The other 
is as though everything is a miracle.”  – Albert Einstein (1879-1955) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Per Louise, Ellen e Paolo
 
”There are only two ways to live your life. One is as though nothing is a miracle.  The other 
is as though everything is a miracle.”  – Albert Einstein (1879-1955) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Per Louise, Ellen e Paolo

ABSTRACT 
 
Introduction: Endometriosis is a common gynaecological disease affecting up to 10% of 
women of reproductive age. The women suffer from severe abdominal pain and infertility as 
a consequence of the chronic inflammation. The disease has also been associated with an 
increased risk of cancer, in particular endometrial and ovarian cancer.  Endometriosis 
represents an important socioeconomic burden as the condition is associated with 
productivity loss, medical and surgical treatments including assisted reproduction, and a 
compromised quality of life.  The pathophysiology of endometriosis is not fully understood, 
and as of today we are unable to identify women at risk for cancer development and offer 
them a tailor-made prophylactic treatment.  
Aims: The overall aim of this thesis is to explore some of the mechanisms that have an 
important influence on clinical impact, in particular infertility and the risk of developing 
endometriosis-associated cancer. The mechanisms enabling endometriotic lesion 
establishment are explored in an in vitro experimental model and the methylation profile of 
the fertility-regulating gene HOXA10 is investigated in eutopic and ectopic endometrium. 
This study also attempts to identify the molecular link between endometriotic stem cells and 
the development of ovarian cancer by exploring CSC-specific markers and their molecular 
signatures, and gene expression profile of cancer-correlated molecules in different 
endometrial compartments. 
Results: Significant changes were found in the endometrium of women with endometriosis 
compared to healthy controls. The first study demonstrated the expression of ApoE, ITGB2, 
ITGB7, LAMC1, CD24, and JAM-1 in women with and without endometriosis. Also, some 
of the molecules showed a significant altered expression upon comparing endometrium from 
women with and without endometriosis, as well as eutopic and ectopic endometrium of 
women with endometriosis. ApoE and JAM-1 were decreased in both proliferative and 
secretory phase in endometrium from women with endometriosis, and mRNA expression of 
LAMC1 was reduced in endometrium from endometriosis patients compared with controls in 
the proliferative phase. CD24 expression was significantly expressed in eutopic and ectopic 
endometrium in women with endometriosis. In the second study, we found a significant 
hypermethylation of the HOXA10 gene in eutopic secretory endometrium in women with 
endometriosis compared with controls. When comparing the methylation profile in patients 
suffering from ovarian endometriosis with patients presenting extra-ovarian disease, we could 
not demonstrate any significant correlation between methylation status and stage of disease. 
The third study demonstrated that mesenchymal endometrial stem cells from women with 
endometriosis showed an active S-phase as well as an up-regulation of PTEN, VEGF-α, and 
decreased BCL2 gene-expression compared to controls. A subset of potentially ‘high-risk’ 
patients could be identified showing a significant up-regulation of genes involved in 
reprogramming SOX2, NANOG; cancer metabolism TP53, K-ras; and epithelial-
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 mesenchymal transition genes TGF-α and SNAI1. TP53 turned out to play the role of a 
master regulator. When comparing monolayer to 3D spheroid cultures, an increased co-
expression of CSC surface markers CD44 and CD133 was seen, and the chemo-sensitivity 
assay performed in a 3D-tumour microenvironment revealed increased tumour invasion in the 
‘high-risk’ group. In the fourth study, we found a significant difference in the expression of 
genes that correlated with endometrial malignant transformation in both endometrial stromal 
and glandular compartments in endometriosis patients compared with controls.  
Conclusions: Our results shed light on the molecular linkage to the etiology of endometriosis 
and malignant transformation of endometriosis, as well as providing useful information 
relevant to endometriosis-associated infertility and pathogenesis. 
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 POPULÄRVETENSKAPLIG SAMMANFATTNING 
En av tio kvinnor i reproduktiv ålder drabbas av endometrios med negativ påverkan på 
livskvalitet och barnafödande som följd. Livmoderslemhinnan som spridits utanför livmodern 
och bildat små ”härdar”, vanligast på äggstockarna och på bukväggen,”menstruerar” varje 
gång kvinnan har sin mens och kan då skapa svåra buksmärtor och kronisk inflammation. 
Sjukdomen innebär för de drabbade kvinnorna ofta långa perioder av sjukskrivning, 
upprepade kirurgiska ingrepp och/eller infertilitetsbehandlingar. I sällsynta fall kan 
endometrios innebära en ökad risk för canceromvandling av livmoderslemhinnan eller 
äggstockscystor. 
Sjukdomens orsaker är fortfarande ofullständigt kända. Många teorier har framförts under 
decennier av forskning inom området och sannolikt är det ett samspel mellan genetiska, 
immunologiska och miljöfaktorer som ligger bakom sjukdomens uppkomst. Den teori som 
genom tiderna har ansetts som den viktigaste är den som bygger på att kvinnor med 
endometrios anses ha ett bakåtflöde vid menstruation (retrograd menstruation) vilket medför 
att blod hamnar i buken via äggledarna. Modern forskning har visat att stamceller skulle 
kunna spela en roll i uppkostmekanismen av endometrios. Stamceller besitter unika 
egenskaper som gör att de kan utvecklas till olika celltyper och skulle därför kunna förklara 
varför  livmoderslemhinnan via retrograd menstruationsflöde lyckas ”invadera” och etablera 
sig utanför sitt ursprungsorgan. Vi har studerat olika stamcellsmarkörer i livmodern och i 
endometrios ”härdar” för att kartlägga deras förekomst hos kvinnor med och utan 
endometrios. Förekomsten av dessa molekyler (ApoE, ITGB2, ITGB7, LAMC1, CD24 and 
JAM-1) kan påverka enodometriecellernas förmåga att fästa och invadera och därmed 
möjliggöra uppkomsten av en endometrioshärd. 
Vi har också studerat hur gener relaterade till infertilitet och cancerutveckling uttrycks i 
livmoderslemhinnan hos kvinnor med och utan endometrios. Vad beträffar infertilitet har vi 
tittat på en gen som är viktig för implantation av det befruktade ägget, HOXA10.        
Tidigare forskning har visat att denna gen är otillräckligt uttryckt hos kvinnor med 
endometrios. Vi har tittat närmare på orsaken till detta förändrade genuttryck och sett att det 
beror på dna-förändringar genom så kallad metylering. Vi har visat att livmoderslemhinnan 
hos kvinnor med endometrios har en mycket högre metylering av denna gen jämfört med 
kvinnor utan endometrios. Metylering är en dna-förändring som är reversibel och vi hoppas 
att vår forskning kan bidra till utveckling av behandlingsmetoder som kan återställa uttrycket 
av denna gen och därmed bidra till förbättrad fertilitet hos kvinnor med endometrios.  
I två studier har vi också undersökt möjliga orsakssamband mellan endometrios och risken 
för cancerutveckling i livmodern och i äggstockarna.  Vi har med olika molekylära tekniker 
såsom cellodlingstekniker, cellsortering och studie av cellcykelfasen undersökt  mesenkymala 
stamceller i livmoderslemhinnan hos kvinnor med och utan endometrios. I denna studie 
användes en cellodlingsmodell där olika typer av cytostatika tillsattes för att bekräfta att de 
celler som har tumörliknande egenskaper uppvisade resistens mot cytostatika. Vi kunde i 
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denna studie identifiera en undergrupp av endometriospatienter som uppvisade ett genuttryck 
liknande den som kan påträffas i cancer.  
I studien där vi undersökte de bakomliggande orsakerna till endometriosassocierad 
livmodercancer kunde vi genom microarray-teknik påvisa att elva gener kopplade till 
cancerutveckling var signifikant annorlunda uttryckta i gruppen av kvinnor med endometrios  
jämfört med kontrollgruppen.  
Då man ej klarlagt sjukdomens exakta uppkomstmekanismer kan man tyvärr fortfarande inte 
erbjuda kvinnor med endometrios en botande eller förebyggande behandling. 
Våra studier bidrar till att utöka kunskapen om sjukdomens bakomliggande orsaker, dess 
påverkan på fertilitet och den möjliga kopplingen till cancerutveckling. Vår förhoppning är 
att dessa resultat kan bidra till fortsatt forskning inom området med målet att förbättra 
möligheten till patientcentrerad, ”skräddarsydd”, behandling och identifiera när det är 
nödvändigt att även erbjuda förebyggande åtgärder för att minska risken för 
cancerutveckling.  
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1 INTRODUCTION 
Around one out of ten women of fertile age suffers from endometriosis, a disease 
characterized by many unresolved questions regarding its pathophysiology, despite decades 
of research dedicated to better understand the complexity of the disease.  
Many aspects still remain poorly understood, a fact that affects the possibilities of curative 
treatment and prevention. What remains beyond doubt is that this group of patients suffers 
from many compromised health aspects, including infertility, chronic pain, and risk of 
endometriosis-associated cancer.  
1.1 PATHOGENESIS OF ENDOMETRIOSIS 
Endometriosis has sometimes sarcastically been nominated “the disease of the theories”, 
elucidating the fact that the disease has a multifactorial origin and its pathogenic complexity 
is yet not fully defined. 
1.1.1 Retrograde menstruation – coelomic metaplasia and implant survival 
The theory of retrograde menstruation, first described by Sampson (Sampson 1927) explains 
endometriosis as a consequence of peritoneal dislocation of endometrial implants.          
Taken together with the theory that endometriosis is induced through a metaplastic process in 
the peritoneal mesothelium called coelomic metaplasia (Matsuura et al., 1999), these have 
been the leading presumptions for many decades. But it’s also known that the prevalence of 
endometriosis is far less than the occurrence of tubal reflux menstruation in women. This 
could possibly be explained by the co-existence of molecular and/or immunologic defects in 
endometriosis (Lucidi et al., 2005). The theory of coelomic metaplasia could still be 
supported for ovarian endometriosis development, as the coelomic epithelium lining the 
peritoneum and ovary can undergo metaplasia (Vercellini et al., 2013).  
The implant survival could then be explained by an altered endometrial gene transcription 
and an increased endometrial invasion induced by the early endometriotic lesion (Nair et al., 
2008), and by failure of the immune system to clear implants from the peritoneal surface 
(Giudice and Kao 2004).  
Another requirement for survival is an hypoxic microenvironment, which supports the 
attachment and implantation of ectopic endometrium with the support of pro-angiogenic 
factors. Hypoxia promotes the expression of downstream genes involved in implantation and 
persistence of ectopic endometrium. Recently published data show a high expression of HIF-
1α, HIF-2α, VEGF-α, PAR-1, and PAR-4 in patients with ovarian endometriosis (Filippi et 
al., 2015; Lu et al., 2014).  
Together with the involvement of immune clearance escape, neuroangiogenesis, matrix 
degradation, this helps lesions survive. Attachment and invasion to ectopic sites may then be 
facilitated by up-regulation of adhesion molecules (Burney 2013). 
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 Sustained cell proliferation and apoptosis avoidance 1.1.1.1
Cumulating evidence suggests that apoptosis regulation in ectopic lesions is supported by an 
up-regulation of anti-apoptotic genes and a coordinated down-regulation of genes involved in 
apoptotic pathways (Sourial et al., 2014).                                                                                
Recent in vivo data emerged in a baboon-model of endometriosis shows that ectopic implant 
survival is facilitated by an overexpression of pro-proliferative markers such as telomerase, 
nucleolin and proliferating cell nuclear antigen (PCNA) and loss of  γ-H2AX expression 
(phosphorylated H2A histone family, member X) (Hapangama et al., 2010).                              
As a consequence endometrial proliferation is sustained by affected DNA-repair recognition 
and evading of apopotosis, in particular in the initial establishment of the disease 
(Hapangama et al., 2010).  
 
1.1.2 Role of endometrial stem cell implantation  
Gargett CE and collaborators have shone a light on the relatively new field of stem cell 
research, and their findings suggest that endometrial stem/progenitor cells could be involved 
in eutopic and ectopic endometrial regeneration and differentiation (Gargett and Masuda 
2010). In the hypothesis first described by Leyendecker et al., more of the basalis layer, 
which contains the endometrial stem/progenitor cells required for the monthly endometrial 
self-renewal, is shed in women with endometriosis. Together with one of the established 
theories of retrograde menstruation, this has led to further research focusing on how 
abnormally-shed endometrial stem/progenitor cells establish ectopic peritoneal implants 
(Gargett 2006, 2007; Leyendecker et al., 2002; Sasson and Taylor 2008). 
Clonogenic cells with stem/progenitor properties have been identified in ectopic 
endometriotic lesions. Chan et al. investigated the colony-forming activity of endometriotic 
epithelial and stromal ovarian endometrioma, and observed a greater proportion of 
clonogenic stromal cells in the proliferative phase. This suggested that endometriotic lesions 
possess a hormone-dependent cell population that under hormonal stimulation in the early 
cycle phase can proliferate and differentiate (Chan et al., 2011). Ectopic endometrial 
mesenchymal stem cells (endometrial MSCs) have been clearly shown to have a greater 
capacity for cell migration and angiogenesis when compared to eutopic endometrial MSCs in 
an in vivo mouse transplant model (Kao et al., 2011). 
Further studies in the field focused upon the aspect of neonatal progesterone-withdrawal 
bleeding and subsequent onset of early pre-menarcheal endometriosis (Brosens et al., 2013; 
Gargett et al. 2014). However, no studies to date have generated direct evidence of the role of 
endometrial stem cells in the pathogenesis of endometriosis (Gargett et al., 2016).  
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1.1.3 Impact of immune system 
The association between inflammation and endometriosis is well known and involves local 
vascularization, somatic cells, and immunocytes. An overproduction of prostaglandins and 
metalloproteinases is seen in women with endometriosis (Bulun 2009). 
It has been debated, however, that endometriosis is a consequence of inappropriate immune 
defence response, or that the pelvic and peritoneal inflammation is a consequence of the 
disease. At present, most evidence supports the latter (Kyama et al., 2003).  
The vast majority of women have some degree of retrograde menstruation (75-90%) (Burney 
and Giudice 2012), but most will never develop the disease. This could partly be explained by 
the fact that an unsatisfactory immune vigilance fails to clear cell/tissue implants from the 
peritoneal surface. The local pelvic inflammatory process with its altered function of immune 
cells in the peritoneal environment is considered to play a pivotal role in evolution of the 
disease.  
 
Several immune aspects are thought to be involved. 
 Cell-mediated immunity 1.1.3.1
The main function of NK (natural killer) cells is to eliminate infected cells as well as tumour 
cells. In women with endometriosis, local and systemic variation in NK cell function as well 
as a decrease in NK-mediated cytotoxicity have been shown (Thiruchelvam et al., 2015). 
These changes contribute to a clearance of defective endometrial cells located in the pelvis 
and correlate to some extent with disease severity. 
Uterine NK cells (uNKs) have a definite NK cell population dedicated to the eutopic 
endometrium undergoing cyclical changes, and which persists and proliferates in case of 
successful implantation. Studies have shown that NK cells present an altered phenotype with 
high expression of the cytotoxic cell surface receptors CD16+ and NKp46+ in women with 
endometriosis, a fact that might play a role in endometriosis-associated infertility.  
However, a recent systematic review and meta-analysis of the potential benefits of immune 
therapy in case of high levels of NK cells and infertility confirmed that there is yet no 
conclusive data to allow evidence-based conclusions (Seshadri and Sunkara 2014).  
An increase in number and activation of peritoneal macrophages has been demonstrated in 
women with endometriosis (Eisenberg et al., 2012). Also, pro-inflammatory chemo-attractant 
cytokines for monocytes, macrophages, and granulocytes have been detected in the peritoneal 
fluid in women with endometriosis. 
Interleukin-1 β has been designated an angiogenetic potential throughout VEGF and IL-6 
activation (Lebovic et al., 2000). 
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Several mechanisms and factors are involved to enhance the establishment of the 
endometriotic cells that have escaped the immune surveillance. Among them are ICAM-1 
that conciliates immunity related cell-to-cell synergies and the Fas-Fas ligand system, which 
mediates cell death of activated immune cells in a pro-inflammatory environment, such as the 
peritoneal fluid in women with endometriosis (Eisenberg et al., 2012). 
 Humoral-mediated immunity 1.1.3.2
Increased B-cell activity and presence of autoantibodies have been shown in women with 
endometriosis. Various autoantibodies have been noted, such as phospholipid antibodies and 
also tissue-specific anti-endometrial and anti-ovarian antibodies. Some authors have in fact 
proposed the investigation of the presence in serum of anti-endometrial antibodies as a 
diagnostic tool (Randall et al., 2007). What is always important to consider is that the 
presence of autoantibodies is not synonymous with autoimmune disease (Lleo et al., 2010). 
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Figure 1 summarizes the role of the immune system in developing and maintaining the 
disease (modified from Kyama et al., 2003, with the author's kind permission). 
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1.1.4 Steroid metabolism dysfunction – attenuated progesterone action 
Traditionally, endometriosis has been considered predominantly an oestrogen-dependent 
disease, but a more recent consensus is that the hormonal dysfunction is also related to 
progesterone regulation and incompetence. Several target genes crucial for successful 
implantation have been reported as deregulated in women with endometriosis (Kao et al., 
2003), many of them correlated with progesterone metabolism and progesterone receptor 
function. The activated progesterone receptor plays a major role in regulating the tissue 
remodelling that the uterus undergoes during menses and pregnancy. A dysfunction of the 
progesterone-regulatory processes, induced by the chronic inflammatory state caused by 
endometriosis, leads to the condition termed progesterone resistance or attenuation      
(Burney et al., 2007). Progesterone resistance can involve the progesterone receptor isoforms 
(PR-A and PR-B) as well as downstream molecules such as TGF, retionoic acid, c-myc, or 
the co-activators of the receptor itself (Burney et al., 2007). In endometriosis tissue, a 
remarkable reduction of PR-A and PR-B levels has been shown (Bulun 2009). 
1.1.5 Genetics 
The role of genetics and epigenetics has in recent years become a hot topic due to efforts to 
better understand the mechanisms of the pathophysiology of endometriosis and its 
impairment on fertility. Endometriosis is clearly heritable, with a sevenfold risk of 
developing the disease in women with an affected mother or sister (Simpson and Bischoff 
2002). Studies on monozygotic twins demonstrate a correlation to disease stage (Hadfield et 
al., 1997). Genes involved in cytokine-related inflammation, steroid and hormone receptors, 
and matrix degradation have been reported to be differentially expressed in women with 
endometriosis (Burney 2013). Even though various genes have been proposed, no robust 
candidates have come to light (Rahmioglu et al., 2012). Genetic association studies, and more 
recently, genome-wide association studies (GWAS) have brought new insights to the field. 
Several GWAS have been conducted on Japanese and European populations and the first one, 
reported in 2010, identified a significant association between endometriosis and rs10965235 
located on the CDKN2BAS gene (cyclin-dependent kinase inhibitor 2B antisense RNA) on 
chromosome 9p21 (Uno et al., 2010). The same study also reported a locus on chromosome 
1p36 containing Wnt4 as a candidate locus for endometriosis (rs 7521902).  
Shortly after, another large GWAS announced an associated signal (rs12700667) on 
chromosome 7p15.2 in an intergenic region near the genes HOXA10 and NFE2L3 (Painter et 
al. 2011). These authors confirmed the results in a larger, independent (and geographically 
different) cohort. Nyholt et al. conducted a meta-analysis that helped confirm the findings of 
of the previous GWAS and also reported five new signals associated with endometriosis in 
European and Japanese populations: rs13394619, rs10859871, rs4141819, rs7739264, and 
rs1537377 (Nyholt et al., 2012). The latest large GWAS identified three new SNPs of 
significance: rs1519761, rs6757804, and rs2235529, which reside near Wnt4 (Albertsen et 
al., 2013).  
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Recently, Sapkota et al. performed an independent replication and meta-analysis for 
endometriosis risk loci for nine of the above mentioned SNP loci (rs7521902, rs13394619, 
rs4141819, rs6542095, rs1519761, rs7739264, rs12700667, rs1537377, and rs10859871). 
The findings provided supporting evidence for associations of the implicated SNP loci with 
endometriosis (Sapkota et al., 2015). 
 Epigenetics 1.1.5.1
Epigenetics is one of the most expanding fields in bio-molecular research. It is characterized 
by a reversible condition, influenced by age and lifestyle factors, that underlies a wide range 
of pathologies. The theory of endometriosis as an epigenetic disease is now well-established 
(Guo 2009). The most frequent and well-documented epigenetic mechanism is DNA 
methylation followed by histone modification and regulation of chromatin modifications. 
Commonly, promoter hypo- and hyper-methylation is related to gene expression and 
silencing, respectively. The first documentation of epigenetic alteration in endometriosis was 
associated with the HOXA10 gene, which showed a hypermethylation in the endometrium of 
women with endometriosis (Wu et al., 2005). The same research group demonstrated further 
that DNA methyltransferases (DNMT1, DNMT3a, and DNMT3b) are highly expressed in 
endometriotic lesions (Wu et al., 2007). These enzymes, by catalysing the process of DNA-
methylation in the endometrium, could affect transcriptional activation or silencing of genes 
crucial for apoptosis and proliferation regulation.  
In their recent GWAS, Naqvi et al. demonstrated 129 genes with altered methylation (59 
hypermethylated and 61 hypomethylated), and with confirming RT-PCR, the authors showed 
several new genes with an altered expression and methylation in endometriosis patients (O-6-
methylguanine-DNA methyltransferase, dual specificity phosphatase 22, cell division cycle 
associated 2, inhibitor of DNA binding 2, retinoblastoma binding protein 7, bone 
morphogenetic protein receptor, type 1B, tumour necrosis factor receptor 1B, zinc finger 
protein receptor 681, immunoglobulin superfamily, member 21, and tumour protein 73) 
(Naqvi et al., 2014).  
Regarding histone modifications, several genes in women with endometriosis have presented 
an altered histone acetylation status, such as ER-α, GPER1, SF-1, HOXA10, C/EBP α, HIF-1 
α, DR6, and E-cadherin (Nasu et al., 2014). The authors also pose the question of many 
researchers involved in the field of epigenetics: To what extent are the alterations a cause or a 
consequence of the disease? 
Thus, the concept of endometriosis as an epigenetic disease is still fairly novel and many 
pieces of the puzzle are still missing. Future research in the field could shed light on risk 
factors, pathogenesis, early diagnosis, prognostic markers, and new treatment strategies.  
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1.2 CLINICAL IMPACT OF ENDOMETRIOSIS 
For a woman affected with endometriosis the clinical impact is considerable.                           
The first aspect regards the diagnostic delay, which is still far too long even though medicine 
and society now have greater knowledge and understanding of the disease (Simoens et al., 
2012; Staal et al., 2016).  
Other aspects include infertility, chronic pain, adverse psychological conditions, affected 
sexual life, and reduced quality of life as a consequence of all these (Moradi et al., 2014).     
In this chapter, the focus will fall on two major aspects that negatively influence the health of 
the woman: reduced reproductive capacity and risk of endometriosis-associated cancer.  
1.2.1 Infertility – the mechanisms 
Endometriosis negatively affects fertility (Giudice 2010). A normal monthly fecundity rate 
(MFR) is 15-20% (MFR 0.15-0.2), while women with untreated endometriosis have an 
estimated MFR less than 0.05 (2-10%) (Holoch and Lessey 2010).  
Up to 50% of infertile women can address endometriosis as the origin of fertility impairment 
(Meuleman et al., 2009). Although it has been debated over the years, the stage of disease is 
correlated with severity of fertility impairment, and it appears that women with severe disease 
are more likely to suffer infertility (Macer and Taylor 2012).  
The infertility that is related to endometriosis is multifactorial and can be attributed to 
processes acting independently or in synergy, with these processes taking place in diverse 
compartments such as the peritoneal cavity, uterus, and ovaries. 
 Pelvic cavity 1.2.1.1
The pelvis is an origin of endometriosis-related infertility based upon several observations. 
Chronic inflammation generates a favourable environment for adhesion development, and 
eventual surgical treatment could aggravate this. Peritubal adhesions may also cause ovarian 
entrapment and decreased tubal motility and as a consequence, sub-optimal ovum transport 
(Liakakos et al., 2001). Such adhesions might also be an important explanation for increased 
infertility in severe stages of endometriosis compared to mild disease involvement.  
The peritoneal fluid in women with endometriosis is an important element because it is the 
site of various aspects of inflammation-induced alterations. Some of these are correlated to 
the aberrant cell-mediated immunity with an inflammatory cascade induced by the increased 
number of activated macrophages, while others are correlated to the presence of cytokines 
and growth factors that are overrepresented in the peritoneal environment due to increased 
leucocyte presence.  
Peritoneal fluid concentrations of RANTES (regulated upon activation, normal T cell 
expressed and secreted), IL-6, IL-1, TNF-α, and VEFG have all been reported to be increased 
in women with endometriosis and to affect sperm survival and capacitation (Gupta et al., 
2008; De Ziegler et al., 2010).  
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Macrophages and leucocytes present in the peritoneal environment generate large amounts of 
reactive oxygen species (ROS), which also are assigned a role in endometriosis-associated 
infertility (Gupta et al., 2006).  
 Ovary 1.2.1.2
A potentially reduced ovarian tissue volume following eventual surgery is a cause of reduced 
fertility (Somigliana et al., 2014). An endometrioma has a negative impact on ovarian fertility 
capacity by generating an inflammatory process (Holoch and Lessey 2010), besides 
compromising the available ovarian tissue by space-occupying effects.  
There is evidence that women with endometriosis present an altered folliculogenesis with a 
slower follicular growth and a reduced dominant follicle size, in part depending upon 
alterations in granulosa cell kinetics and apoptosis, and with the negative influence of 
oxidative stress (Gupta et al., 2008).  
Moreover, concentrations of a large number of molecules appear increased in the follicular 
fluid (FF) in affected women. These include TNF-α (Falconer et al., 2009); the interleukins 
IL-6, IL-1β, IL-8, IL-1α, and IL-10; VEGF; and  NK-cells, macrophages, and B-lympocytes 
(Gupta et al., 2008).  
The role of nitric oxide (NO) and its influence on the follicular microenvironment has also 
been assigned an important role in adequate folliculogenesis, and a deregulated NO has been 
discovered in the FF of endometriosis patients (Goud et al., 2014). These findings support the 
hypothesis that a dysregulation of NO affects follicular health negatively with an increased 
granulosa cell apoptosis and reduced oocyte quality as a consequence.  
As previously mentioned, aromatase activity plays a role in the pathogenesis of the disease 
(Bulun et al., 2005), and the increased level of IL-6 found in the FF cause a decreased 
aromatase activity across the mitogen-activated protein kinases (MAPK) pathway.             
The final result is a decreased level of E2 in the FF, negatively affecting fertilizing capacity 
(Gupta et al., 2008). 
 Impact on the endometrium 1.2.1.3
The healthy endometrium manages to sustain an equilibrium that permits ovulation, 
implantation, and menstruation to be established with a balanced steroid action of oestrogen 
and progesterone. An imbalance between these hormones, with an oestrogen dominance and 
progesterone resistance associated with chronic inflammation, appears to be crucial in the 
pathogenesis of endometriosis (Lessey and Young 2014). Evidence supports that 
endometriosis influences the eutopic endometrium even though the mechanisms on the 
molecular level are poorly understood (Macer and Taylor 2012). Endometrial receptivity is 
also altered due to aberrant expression of cell adhesion molecules, among them integrins.     
In particular, the αvβ3 integrin expression, required during the implantation window, has 
 
 9 
Macrophages and leucocytes present in the peritoneal environment generate large amounts of 
reactive oxygen species (ROS), which also are assigned a role in endometriosis-associated 
infertility (Gupta et al., 2006).  
 Ovary 1.2.1.2
A potentially reduced ovarian tissue volume following eventual surgery is a cause of reduced 
fertility (Somigliana et al., 2014). An endometrioma has a negative impact on ovarian fertility 
capacity by generating an inflammatory process (Holoch and Lessey 2010), besides 
compromising the available ovarian tissue by space-occupying effects.  
There is evidence that women with endometriosis present an altered folliculogenesis with a 
slower follicular growth and a reduced dominant follicle size, in part depending upon 
alterations in granulosa cell kinetics and apoptosis, and with the negative influence of 
oxidative stress (Gupta et al., 2008).  
Moreover, concentrations of a large number of molecules appear increased in the follicular 
fluid (FF) in affected women. These include TNF-α (Falconer et al., 2009); the interleukins 
IL-6, IL-1β, IL-8, IL-1α, and IL-10; VEGF; and  NK-cells, macrophages, and B-lympocytes 
(Gupta et al., 2008).  
The role of nitric oxide (NO) and its influence on the follicular microenvironment has also 
been assigned an important role in adequate folliculogenesis, and a deregulated NO has been 
discovered in the FF of endometriosis patients (Goud et al., 2014). These findings support the 
hypothesis that a dysregulation of NO affects follicular health negatively with an increased 
granulosa cell apoptosis and reduced oocyte quality as a consequence.  
As previously mentioned, aromatase activity plays a role in the pathogenesis of the disease 
(Bulun et al., 2005), and the increased level of IL-6 found in the FF cause a decreased 
aromatase activity across the mitogen-activated protein kinases (MAPK) pathway.             
The final result is a decreased level of E2 in the FF, negatively affecting fertilizing capacity 
(Gupta et al., 2008). 
 Impact on the endometrium 1.2.1.3
The healthy endometrium manages to sustain an equilibrium that permits ovulation, 
implantation, and menstruation to be established with a balanced steroid action of oestrogen 
and progesterone. An imbalance between these hormones, with an oestrogen dominance and 
progesterone resistance associated with chronic inflammation, appears to be crucial in the 
pathogenesis of endometriosis (Lessey and Young 2014). Evidence supports that 
endometriosis influences the eutopic endometrium even though the mechanisms on the 
molecular level are poorly understood (Macer and Taylor 2012). Endometrial receptivity is 
also altered due to aberrant expression of cell adhesion molecules, among them integrins.     
In particular, the αvβ3 integrin expression, required during the implantation window, has 
  10 
been reported to be deficient in women with endometriosis (Macer and Taylor 2012; Garrido 
et al., 2003).  
Other molecules relevant to endometrial receptivity and altered in endometriosis involve      
L-selectin ligand and LIF. A reduced LIF expression supports a harmful NO release with 
negative effects on endometrial receptivity-related biomarkers as a consequence (Lessey and 
Young 2014), while a reduced L-selectin expression compromises the adhesion of the 
embryo to the endometrium (Lessey et al., 2013). In addition, the extracellular matrix ligand 
of αvβ3 integrin, IL-11, ICAM and osteopontin, is aberrantly expressed in women with 
endometriosis (Hapangama et al., 2012; Lessey et al., 2013). The role of Wnt7a has also 
recently been emphasized. The Wnt7a protein product is important for development of the 
female genital tract, but also for maintenance of adult uterine plasticity expression. Up-
regulation of Wnt7a might interfere with the mechanisms essential for successful 
implantation (Macer and Taylor 2012). It’s also been known since the late 1990’s that HOX 
genes from the A cluster present an aberrant expression in eutopic endometrium in women 
with endometriosis, and a lack of HOXA10 and HOXA11 mRNA increase during the 
implantation window, which could be one of the possible mechanisms of infertility in these 
patients (Taylor et al., 1999). DNA-methylation has been attributed as responsible for the 
reduced expression of HOXA 10/11 genes. A significant hypermethylation of the promotor of 
the HOXA 10 gene in eutopic mid-secretory endometrium in women with endometriosis has 
recently been demonstrated (Fambrini et al., 2013).  
Thus, cumulative evidence supports that endometriosis negatively influences the fertility 
properties of the endometrium, but many mechanisms behind this still remain unclear.    
Future research in the field is necessary to better understand the linkages at the cellular and 
molecular level in order to prevent implantation failure in these women.  
 
1.2.2 Endometriosis and cancer – molecular links and role of cancer stem cells 
Endometriosis has been associated with gynaecological as well as non-gynaecological cancer. 
Evidence for the latter is yet not satisfactory and is often associated with conflicting results. 
The non-gynaecological cancers that have been reported as correlated with endometriosis are 
cutaneous melanoma (Kvaskoff et al., 2007; Melin et al., 2007), brain cancer (Melin et al., 
2006, 2007), non-Hodgkin lymphoma (Kvaskoff et al., 2015), thyroid and renal cancer 
(Melin et al., 2006).  
In literature, ovarian cancer is the most represented of the endometriosis-associated 
gynaecological cancers first described by Sampson in 1925 (Kvaskoff et al., 2015).            
The phenomenon has since been studied extensively, and many different types of studies 
confirm that women with endometriosis are exposed to an increased risk of certain histologic 
subtypes of ovarian cancer (Aris 2010; Heidemann et al., 2014; Pearce et al., 2012). Of the 
five sub-groups of ovarian cancer (high- and low-grade serous, clear-cell, endometroid, and 
mucinous) an increased risk for clear-cell and endometroid invasive ovarian cancer has been 
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shown in women with endometriosis (Aris 2010; Kobayashi et al., 2008; Zafrakas et al., 
2014). As recently reported in a pooled analysis of more than 13,000 women, there is also an 
increased risk of low-grade serous invasive ovarian cancer (Pearce et al., 2012). Studies have 
also reported a better survival rate among women with ovarian cancer and co-existing 
endometriosis, suggesting that women with endometriosis, in countries where health care 
access is guaranteed, might undergo a higher number of ultrasound scans and thereby 
increase their chance of earlier diagnosis (FIGO I-II stage) (Heidemann et al., 2014). Whether 
parity actually helps lower the risk of ovarian cancer has been investigated and a positive 
trend can be seen even if statistical significance was not reached (Melin et al., 2007). 
Regarding breast cancer, the available evidence suggests a modest increase in risk even 
though no studies have been conducted with stratification for breast cancer type, molecular 
subtype, or hormone receptor status (Kvaskoff et al., 2015).  
Epidemiological studies have demonstrated a decreased risk of cervical cancer (Melin et al., 
2006, 2007) and the same authors have also reported an increase in endometrial cancer risk 
(Melin et al., 2006). Many studies that did not show an increased risk of endometrial cancer 
had a low sample size (Kvaskoff et al., 2015) and further studies are required before 
establishing a lack of association. However, a study including 454 women demonstrates a 
clear linkage between endometriosis and endometrial cancer (Zucchetto et al., 2009) and 
there’s evidence of a risk of endometrial cancer in women with adenomyosis (Baba et al., 
2016; Koike et al., 2013; Kok et al., 2015). 
 Molecular links 1.2.2.1
Endometriosis shares many characteristics with cancer such as the capacity to avoid 
apoptosis, self-regulation of proliferation, and properties that generate angiogenesis (Pollacco 
et al., 2012). 
In terms of apoptosis, the focus has been put on B-cell lymphoma 2 protein (BCL-2) and 
protein 53 (p53), as the first is an anti-apoptotic regulatory protein and the latter is a DNA-
repair regulator and signals apoptosis when required (Pollacco et al., 2012). BCL-2 is 
overexpressed in ovarian carcinoma and one study demonstrated an overexpression in 23% of 
endometriotic cysts. The same authors could not find any up-regulation of p53 in any of the 
benign cysts, while an up-regulation was seen in the ovary affected by endometriod ovarian 
cancer (Nezhat et al., 2002). However, the sample size was rather limited and other authors 
have confirmed an overexpression of p53 in atypical endometriosis and EAOC (Saintz De La 
Cuesta et al., 2004). 
Another crucial aspect for malignant transformation of an endometriotic cyst is the loss of 
ARID1A function. The lack of expression of this tumour suppressor has been considered a 
key event in early molecular malignant transformation leading to endometriosis-associated 
ovarian cancers. (Ayhan et al., 2012). 
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Other molecular events with potential influence on malignant transformation of 
endometriosis tissue include PTEN silencing (Catasús et al., 2004; Cho et al., 2009; 
McConechy et al., 2014; Pardal et al., 2003; Sato el al., 2000), K-ras and CTNNB1 mutations 
(Amemiya et al., 2004; McConechy et al., 2014), and HNF-1β activation (Gadducci et al., 
2014; Kato et al., 2006).  
 Role of cancer stem cells 1.2.2.2
Cancer stem cells (CSCs), a subpopulation of cancer cells possessing tumour-initiating 
capability, have been identified in a variety of carcinomas using different combinations of 
cell-surface antigens and intracellular proteins, and are considered a critical population for 
tumour progression. Recent reports underline the importance of CSCs in tumour progression, 
recurrence, and drug resistance (Ye et al., 2014).  
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(Mirantes et al., 2013).  
Regarding markers for CSCs, in ovarian cancer early progenitor cells are associated with 
specific surface markers like CD133 and CD117 (Bapat 2010; Curley et al., 2009; Kusumbe 
et al., 2009; Liu et al., 2010). Aldehyde dehydrogenase 1 (ALDH1) has been considered 
reliable in investigating various human cancer stem cells (Deng et al., 2010; Ma and Allan 
2011). In association with the expression of the CD133 antigen, ALDH1 represents a useful 
ovarian cancer stem cell marker (Kryczek et al., 2012). 
Oct 4 (POU5F1) is a known transcription factor with functions relevant to pluripotency and 
cell survival, and is associated with several somatic tumours such as lung, gastric, colorectal, 
rectal, bladder, breast, prostate, and ovarian cancers (Ben-Porath et al., 2008; Cheng et al., 
2007; Peng et al., 2010; Rizzino 2009).  
Other CSC markers are SOX2 (Liang et al., 2012) and NANOG (Wang et al., 2013), while 
stem cell signalling markers are represented by notch (Shah et al., 2013), CTNNB1 
(McConechy et al., 2014), and SMO (Chen et al., 2007). Musachi-1 has been attributed to 
asymmetric division (Götte et al., 2008), while TGF-β (Lamouille et al., 2014), SNAI1 (Dang 
et al., 2011; Lamouille et al., 2014), and HIF1α (Liang et al., 2012) are involved in epithelial-
mesenchymal transition (EMT) associated pathways. E-cadherin represents another molecule 
with a pivotal role in morphogenesis, tumour genesis, signal transduction, and EMT 
(Gumbiner 2005; Lamouille et al., 2014; Zohn et al., 2006) In addition, VEGF, known for 
decades to play a crucial role in angiogenesis (Leung et al., 1989), has lately been recognized 
as very important for tumour initiation and function (Goel and Mercurio 2013). 
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CSCs reside in niches, which are distinct anatomical regions within the tumour 
microenvironment. The niches are essential for CSCs as they guarantee a shelter from the 
immune system vigilance as well stemness phenotype preservation (Plaks et al., 2015).       
The niches, with an altered cytokine network and extracellular matrix cross-talk, enable the 
processes involved in tumour initiation and progression, finally contributing to a metastatic 
potential. Among the molecules involved in these mechanisms are VEGF, TGF-β, MMPs, 
Wnt, PDGF, IGF, SDF-1, FGF, EGF, HGF, Wnt, Notch ligand, and Hedgehog ligands, all 
produced by cells in the microenvironment (Ye et al., 2014). These niche molecules are 
suggested to support CSC plasticity and self-renewal, as well as offer a barrier for drug 
delivery (Ye et al., 2014).  
 
1.2.3 Chronic disease development 
 Autoimmune diseases 1.2.3.1
Besides cancer, endometriosis has been associated with inflammatory and autoimmune 
diseases. Studies have revealed an increase in incidence of systemic lupus erythematosus 
(SLE), multiple sclerosis, rheumatoid arthritis (RA), and Sjögren Syndrome (SS) (Harris et 
al., 2015; Sinaii et al., 2002). In a Danish study of 37,661 women with endometriosis, a 
significant risk of SLE, SS, and MS was observed (Nielsen et al., 2011). A large Swedish 
cohort study demonstrated a significant association between endometriosis and celiac disease 
(Stephansson et al., 2011), and another Danish study also presented evidence for a positive 
association between endometriosis and inflammatory bowel diseases (ulcerative colitis and 
Crohn’s disease) (Jess et al., 2012).  
Features similar to autoimmune disease include polyclonal B lymphocyte activation and T/B-
lymphocyte immunological activation as well as elevated levels of cytokines and decreased 
apoptosis (Nothnick 2001). 
In terms of autoantibodies, it’s important to first state that their presence is not synonymous 
with autoimmune disease, as they are also found in healthy subjects and in many conditions 
including cancer (Lleo et al., 2010). Further, natural antibodies may play a role in 
inflammation prevention and their role in autoimmunity is yet to be defined (Lleo et al., 
2010). 
 Other health conditions related to endometriosis 1.2.3.2
The existing literature on allergies and asthma associated with endometriosis is scarce, but 
the available evidence shows an increased risk of atopic allergy and asthma in women with 
endometriosis compared to controls (Bungum et al., 2014).  
Regarding cardiovascular diseases, a recent study (Nurses’ Health Study II) found an 
increased risk of myocardial infarction (RR 1.52), angina pectoris, and coronary artery by-
pass surgery (Kvaskoff et al., 2015). An hypothesis for this increased risk of coronary heart 
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disease (CHD) is the chronic inflammation condition and oxidative stress present in 
endometriosis patients, as well as altered levels of low-density lipoprotein (Kvaskoff et al., 
2015).  
In relation to pregnancy and pregnancy related complications, a recent systematic review 
reveals that there’s evidence for an increased risk of miscarriage, preterm birth, and shorter 
gestational age, as well as an elevated risk for placenta previa (Leone et al., 2016).              
The authors emphasise that current findings do not require any changes in surveillance of 
women with endometriosis during their pregnancy, but physicians should be aware of the risk 
of placenta previa. 
1.2.4 Socio-economic impact and quality of life aspects 
Women affected by chronic pelvic pain are at high risk of psychological stress and the 
condition might interfere considerably with daily life activities, including causing anxiety and 
depression (Weijenborg et al., 2007). Many studies on the quality of life of women affected 
by endometriosis provide clear evidence that their quality of life is compromised on many 
fronts, such as severe dysmenorrhea and dyspareunia, infertility, and altered work capacity 
with lost days at work, as well as surgery-related problems. The overall annual cost for 
endometriosis in Europe due solely to lost days at work has been estimated at 30 billion 
Euros (D' Hooghe and Hummelshoj 2006). 
Diagnostic delay, which is about 6.7 years in symptomatic women (Nnoaham et al. 2011), is 
considered to be a consequence of either patient or doctor responses. (Ballard et al., 2006).   
At the patient level, there’s a tendency to normalise the symptoms as well as a fear of being 
unable to cope. Doctors’ reasons for delaying diagnosis are due to normalization or 
trivialization of pain symptoms, intermittent suppression of symptoms caused by 
contraceptives, or misdiagnosis due to lack of knowledge (Ballard et al., 2006). For assessing 
quality of life in relation to health status, a commonly used instrument is the EQ-5D, 
developed by EuroQol Research Foundation (http://www.euroqol.org). This survey 
methodology defines the health-related quality of life in five dimensions (mobility, self-care, 
usual activity, pain/discomfort, and anxiety/depression). Every dimension is further rated at 
three levels: ‘no problem’, ‘some problem’, or ‘major problem’. A recent, prospective 
multicentre study conducted in ten countries has evidenced the aspects of costs and quality of 
life related to endometriosis (Simoens et al., 2012). The study showed that 56% reported pain 
and discomfort problems, 36% expressed problems with anxiety/depression, and 29% 
reported obstacles with usual activities.  
In terms of the economic burden of endometriosis on healthcare, the EndoCost Study 
conducted by the World Endometriosis Research Foundation looked at the cost of treating 
women in referral centres in ten different countries. The results showed that endometriosis is 
an economic burden (with annual direct health care costs of €3113 per patient), similar to 
other chronic disease such as diabetes, RA, and Crohn’s disease. Further, indirect costs 
(mainly related to productivity loss) were double the direct health costs (Simoens et al., 
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2012). In that study, quality of life was the most decisive predictor of direct health care costs 
and total costs. 
In conclusion, we can state that endometriosis carries a considerable socioeconomic burden. 
The reasons for this are many, including the chronic nature of a disease characterized by 
insufficient knowledge of its complex and multifactorial pathogenesis, further aggravated by 
a significant diagnostic delay.  
The need for future research in this field is critical. We need to develop efficient diagnostic 
therapeutic strategies and thereby improve the quality of life for this vast patient group, and at 
the same time reduce the substantial economic burden that endometriosis represents to 
society.  
 
 
 
2 AIMS 
The overall aim of this thesis is to explore some of the mechanisms that have an important 
influence on clinical impact, infertility, and risk of malignancy. 
The specific objectives were to:  
• Study the invasion of endometrial stem cells and establishment of endometriotic 
lesions in an in vitro experimental model.  
• Investigate the methylation profile of the HOXA10 gene in eutopic and ectopic 
endometrium. 
• Identify the molecular link between endometriotic stem cells and the development 
of ovarian cancer by exploring CSC-specific markers and their molecular 
signatures. 
• Explore the gene expression profile of known cancer-correlated molecules in different 
endometrial compartments in order to better understand the potential malignant 
transformation of the eutopic endometrium in patients with endometriosis.  
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3 MATERIALS AND METHODS 
More detailed description of the materials and methods is provided in the original articles 
(Study I-II) and manuscripts (Study III-IV). 
3.1 SUBJECTS 
All subjects in the studies were between 18-42 years old. All women had regular menstrual 
cycles (25-32 days), and any hormonal treatment or intrauterine device three months prior to 
sample collection was an exclusion criteria. Endometriosis patients in the study had 
previously been diagnosed for endometrioma. 
3.2 ETICHAL PERMITS 
The studies included in this thesis were approved by the regional ethics committee in 
Stockholm (2008-1566-31/3 and 2013/1960-31/4). Written informed consent was obtained 
from all participating subjects. 
3.3 GENERAL METHODS 
3.3.1 Endometrial biopises 
Endometrial biopsies were obtained in all four studies using Randall curette (Stille, 
Stockholm, Sweden), Pipelle curette (Cooper Surgical, Trumbull, USA), or Endoram device 
(RI-MOS, Modena, Italy). In Study I, the samples were obtained both in the proliferative 
phase and secretory phase; in Study II and IV only in the luteal phase; while Study III did not 
require any timed biopsy for the patient sample when luteal phase biopsy (LH+6) was used 
for controls.  
Endometrial samples were processed with RNA-later (Study I and II). In Study III, the tissues 
were transported to the cell culture lab in HAMF10 (Gibco®Life Technologies, Sweden) 
with antibiotics. For Study IV, part of the endometrial tissue was immediately frozen in liquid 
nitrogen. Endometrial dating was performed histopathologically to verify the phase of the 
menstrual cycle according to Noyes criteria (Noyes et al., 1975). 
3.3.2 RNA extraction and cDNA preparation (Study I, III and IV) 
RNA extraction was performed by using TRIZOL®reagent (Invitrogen, Carlsbad, CA, USA) 
in Study I. Picopure RNA extraction kit (Arcturus® PicoPure®Applied Biosystems, Foster 
City, CA, USA) was used for RNA extraction in Studies III and IV. Extracted RNA was then 
treated with RQI RNase-free DNase (Promega Biotech AB, Stockholm, Sweden) and 
subsequently reverse-transcribed using Superscript™ II RNase H-Reverse Transcriptase Kit 
(Invitrogen). In Study III, Purelink® micro RNA isolation kit was used to isolate RNA, and 
SuperScript® VILOTM (Life Technologies, Sweden) was used for cDNA synthesis. 
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3.3.3 Real-time PCR (Study I, III, and IV) 
For real-time PCR analysis, Taqman Universal PCR Master Mix (Applied Biosystems, Foster 
City, CA, USA ) was used with 18S as an internal housekeeping gene. StepOne Plus 
Instrument (Applied Biosystems) was used for Study III and IV. Taqman gene expression 
assays were applied to obtain ΔCT values. The details of primers used are given in 
Supplementary Table 1 (Manuscript Study III) and in Supplementary Table 1 (Manuscript 
Study IV).  
The mean CT value of 18S was subtracted from the CT value of the target gene from the 
respective sample. The differential expression for the specific gene (ΔΔCT ) was calculated 
by subtracting the mean ΔCT of the housekeeping gene from the ΔCT of the target gene 
(Schmittgen and Livak 2008). Mean ΔCT differences from all samples were then converted to 
scientific format (2-ΔCT) according to current Nature protocol published for analysing real-
time PCR data analysis using comparative CT method (Schmittgen and Livak 2008).  
3.3.4 Analysis of molecular interaction and biofunctional pathways (Study III and 
IV) 
Ingenuity® Pathway Analysis software (IPA, Qiagen Inc. USA) was used to explore the 
molecular interactions and biological pathway analysis of the altered genes relevant to 
ovarian cancer development within the EnSC and EndoSC patient groups (Study III) and of 
genes associated with malignant transformation of the endometrium (Study IV).  
 
3.4 STUDY I 
3.4.1 Immunohistochemistry 
Endometrial tissues were fixed in paraformaldehyde and the paraffin sections were used for 
immunohistochemistry (IHC). MACH3™ Mouse-Probe HRP-polymer kit or MACH3™ 
Rabbit-Probe HRP-polymer kit (Biocare Medical, CA, USA) were used for all 
immunohistochemical stainings and counterstained with Mayer’s haematoxolyn. Negative 
mouse IgG isotype control (N1698, Dako, Carpinteria, CA, USA) or ChromPure Rabbit IgG 
(011-000-003, Jackson Immunoresearch, West Grove, PA, USA) were used.                      
Two independent observers scored the slides blindly according to the following staining 
intensity criteria: 0= no staining, 1= weak staining, 2= moderate staining, and 3= strong 
staining. The percentage of stained cells was graded as follows: 0= no staining, 1= <10%, 
2=11-50%, 3= 51-80%, and 4= >81%. The two scores were then multiplied to generate the 
final score. 
3.4.2 Statistical analysis 
The Kruskal-Wallis test was used to compare the independent groups, followed by multiple 
comparisons with Dunn’s correlation. A P-value less than 0.05 was considered statistically 
significant.  
 
 17 
3.3.3 Real-time PCR (Study I, III, and IV) 
For real-time PCR analysis, Taqman Universal PCR Master Mix (Applied Biosystems, Foster 
City, CA, USA ) was used with 18S as an internal housekeeping gene. StepOne Plus 
Instrument (Applied Biosystems) was used for Study III and IV. Taqman gene expression 
assays were applied to obtain ΔCT values. The details of primers used are given in 
Supplementary Table 1 (Manuscript Study III) and in Supplementary Table 1 (Manuscript 
Study IV).  
The mean CT value of 18S was subtracted from the CT value of the target gene from the 
respective sample. The differential expression for the specific gene (ΔΔCT ) was calculated 
by subtracting the mean ΔCT of the housekeeping gene from the ΔCT of the target gene 
(Schmittgen and Livak 2008). Mean ΔCT differences from all samples were then converted to 
scientific format (2-ΔCT) according to current Nature protocol published for analysing real-
time PCR data analysis using comparative CT method (Schmittgen and Livak 2008).  
3.3.4 Analysis of molecular interaction and biofunctional pathways (Study III and 
IV) 
Ingenuity® Pathway Analysis software (IPA, Qiagen Inc. USA) was used to explore the 
molecular interactions and biological pathway analysis of the altered genes relevant to 
ovarian cancer development within the EnSC and EndoSC patient groups (Study III) and of 
genes associated with malignant transformation of the endometrium (Study IV).  
 
3.4 STUDY I 
3.4.1 Immunohistochemistry 
Endometrial tissues were fixed in paraformaldehyde and the paraffin sections were used for 
immunohistochemistry (IHC). MACH3™ Mouse-Probe HRP-polymer kit or MACH3™ 
Rabbit-Probe HRP-polymer kit (Biocare Medical, CA, USA) were used for all 
immunohistochemical stainings and counterstained with Mayer’s haematoxolyn. Negative 
mouse IgG isotype control (N1698, Dako, Carpinteria, CA, USA) or ChromPure Rabbit IgG 
(011-000-003, Jackson Immunoresearch, West Grove, PA, USA) were used.                      
Two independent observers scored the slides blindly according to the following staining 
intensity criteria: 0= no staining, 1= weak staining, 2= moderate staining, and 3= strong 
staining. The percentage of stained cells was graded as follows: 0= no staining, 1= <10%, 
2=11-50%, 3= 51-80%, and 4= >81%. The two scores were then multiplied to generate the 
final score. 
3.4.2 Statistical analysis 
The Kruskal-Wallis test was used to compare the independent groups, followed by multiple 
comparisons with Dunn’s correlation. A P-value less than 0.05 was considered statistically 
significant.  
  18 
3.5 STUDY II 
3.5.1 DNA-extraction and sodium-bisulfite DNA modification 
BioRobot EZ1 (QIAGEN, Hilden, Germany) was used for genomic DNA extraction from 
endometrial samples. Incubation with high-bisulfte salt concentration converted 
unmethylated cytosine into uracil, while methylated cytosines remained unaffected according 
to the manufacturer’s protocol (EpiTect Bisulfite Kit, Qiagen, Germany). 
3.5.2 PCR amplification/Pyrosequencing analysis 
DNA amplification of a CpG-rich fragment within the HOXA10 gene promoter in the 5’ 
region up-stream of the exon 1 (F1) was used, as previously described (Wu et al., 2005).      
The amplified region was analysed using real-time DNA-sequencing technology 
(Pyrosequencing Biotage, Westborough, MA, USA). Two sequencing primers designed 
through Assay Design software 1.0 (Biotage) were used: sequences 1 and 2, identifying 11 
and 8 CpG sites respectively: seq 1: GAAATTAAATTGGGAGT, and seq 2: 
TTTTGGTTTATTAATATAGA. 
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CD105-PE (Abcam, UK), and then sorted using the MoFLOW® XDP flow cell-activated cell 
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characterized for their differentiation into MSC lineages (adipocytes, osteocytes, and 
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antibodies against Osteocalcin and Agreccan markers (R&D Systems, Sweden) and HCS 
LipidTOXTM green neutral lipid reagent (Molecular Probes® Life Technologies, Sweden). 
3.6.2 Cell proliferation and cell cycle analysis 
Expanded endometrial MSCs from endometrium from controls (H-EnSC), cases (P-EnSC), 
and from endometrioma (P-EndoSC) were evaluated for their proliferative activity and cell 
distribution within different phases of cell cycle. Cancer cell lines SKOV3 and Ishikawa were 
used as positive and negative controls, respectively, in the presence and absence of BrDU. 
Cell distributions were categorized by gating for different phases in cell cycle using FACS 
pseudodot plots. Real Time PCR (RT-PCR) using Taqman® gene expression assays for 
proliferation and apoptosis markers confirmed results.  
3.6.3 Spheroid cultures 
Monolayer MSCs from all groups were plated on Corning® ultra-low attachment 6 well 
plates (Thermo Fischer Scientific Inc., USA) with tumour sphere conditioning medium 
containing EGF, BFGF, B27 supplement and insulin. They were allowed to grow into second 
generation spheres the size of >50 um for 10-12 days. They were used in studies with RT-
PCR, FACS characterization, and immunofluorescence for comparing markers of MSCs. 
3.6.4 Classification of a potential high-risk subgroup of patients 
Univariate and multivariate models with SIMCA 14 software (Umetrics AB, Sweden) were 
used to assess intragroup variability. Principle component analysis (PCA) was used to 
achieve the highest possible predictability, and with scatter plot distribution of patients, we 
sub-classified those patients who were close to or away from a 95% confidence interval (CI) 
in both EnSC and EndoSC as potential ‘high-risk’ or ‘low-risk’ patient subgroups. 
Gene-loading plots revealed a distribution of specific genes that contribute to ‘high-risk’ 
status by showing a distribution analogous to that of patients in the scatter plot. Identified 
potential risk groups and their regulated genes were further defined for higher predictability 
at the multi-parametric level using an orthogonal partial least squares-descriptive analysis 
(OPLS-DA).  
To confirm aberrantly-regulated crucial pathways among the sub-groups, heat maps were 
generated by GENE-E software version 3.0.224 (Broad Institute Inc. Cambridge, MA, 
USA.). Trend curves were then created to compare expression trends between potential ‘high-
risk’ and ‘low-risk’ patients in comparison with validated cancer cell lines and healthy 
volunteers.  
3.6.5 Flow cytometry characterization 
All MSC groups were analysed for surface expression of stromal markers CD146-PerCP-
cy5.5, SUSD2/W5C5-APC (Biolegend, San Diego, CA, USA), CD10-FITC (Miltenyi 
Biotec, Bergisch Gladbach, Germany); epithelial markers SSEA1-Alexa fluor 488 (Santa 
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Cruz biotechnology, CA, USA), EPCAM-PE (Miltenyi Biotec), cytokeratin18-PE (BD 
Horizon, Piscataway, NJ, USA); as well as hematopoietic lineage markers CD45-APC, 
CD34-APC, CD20-PerCP, and CD3-FITC (BD Pharmingen, Franklin Lakes, NJ, USA). 
Their expression was compared in terms of median fluorescent intensity (MFI) with respect 
to their unstained controls, and results were rendered in histograms using FlowJo data 
analysis software (LLC, Oregon). 
Monolayer MSCs were compared with their respective in vitro-generated spheroid MSCs 
from all patient and healthy controls for CSC markers ALDH1 by Aldefluor assay (Stem cell 
technologies, Vancouver, Canada) and anti-human antibodies CD133-1-APC (Miltenyi 
Biotec), CD44-PE (Biolegend), CD117-PE-cy7 (Biolegend), and ABCG2-PerCP-cy5.5 
(Biolegend). Co-expression of CSC markers between monolayer and spheroid MSCs were 
represented in pseudodot plots, while the individual marker expression of both cultures were 
shown in histograms.  
3.6.6 Co-localization of CSC marker proteins 
Dual colour immunofluorescence was used for observation of co-expression of CSC marker 
proteins in spheroid MSCs. Anti-human OCT3/4 antibody (Santa Cruz Biotechnology, TX, 
USA), rabbit polyclonal PROM1/CD133 (Biorbyt, Cambridge, UK), and CD44variant 6 
(Molecular Probes® Life Technologies) were used as primary antibodies. As a positive 
control, SKOV3 ovarian cancer line was used. Stained spheres were incubated overnight and 
tagged with secondary antibodies; donkey anti-mouse alexa fluor 488 (Molecular Probes® 
Life Technologies) and goat anti-rabbit Abberior® STAR633 (Abberior, Göttingen, 
Germany).  
Co-localization of CSC markers was visualized in the following combinations: OCT3/4 and 
CD133, CD44v6 and CD133. Images were captured using Zeiss LSM 700 confocal 
microscopy (Carl Zeiss, Tokyo, Japan) and for construction, a co-localization dot plot created 
with Huygens software (Scientific Volume Imaging, Hilversum, Netherlands) was used. 
3.6.7 Chemo-sensitivity and tumour invasion assay 
To assess the potential invasiveness and drug-resistance capacity among endometrium of 
patients (P-EnSC and EndoSC), a 3D-tumour invasion model was designed according to 
protocols provided by Cultrex® 3D Spheroid Fluorometric Proliferation/viability assay kit 
and Cultrex® 3D Spheroid Invasion assay kit (Trevigen Inc. Gaithersburg, MD, USA). 
Harvested cells were suspended, seeded in a 96 well low attachment plate (Corning), and 
incubated under hypoxic conditions (2% O2) for 72 hours. The MSC drug resistance 
capability was assessed by subjecting cultures to increasing doses of Paclitaxel (0.1, 1, 10nM) 
and Cisplatin (0.1, 1, 10µM). At the end of the treatment, one-tenth volume of Resazurin was 
added and resorufin was read at 590nm. In addition, invasion was assessed in response to 
chemo-resistance by performing the above steps until spheroid expansion, then invasion 
media along with addition of chemo-attractants MCF-1. Media containing presence/absence 
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of Paclitaxel (10nM) or Cisplatin (10µM) was later added and incubated for 8 days. Images 
were captured from the time of adding invasion media using live cell instrument (Leica) and 
assessed every other day. Images were processed for calculating invasion area using ImageJ 
software.  
3.6.8 Statistical analysis 
Groups from both monolayer and spheroid endometrial MSCs were checked for Gaussian 
distribution using Shapiro-Wilk’s normality test, and homogeneity of variance using 
Bartlett’s Test. Groups that had P>0.05 in both tests were considered parametric. 
For comparing EnSC and EndoSC, a paired T- test was used, while the Wilcoxon Signed T-
test was used if groups were paired and non-parametric. Similarly, for unpaired groups, either 
an unpaired T-test or Mann-Whitney test was performed. For chemo-sensitivity assay, a two-
way Annova test was used.  
Statistical software GraphPad Prism 6 (GraphPad Software Inc., La Jolla, CA, USA) was 
used. 
3.7 STUDY IV 
3.7.1 Laser capture micro-dissection (LCM) 
Fresh frozen sections (9 µm) were placed and fixed on a membrane slide (Membrane Slide 
NF 1.0 PEN, Carl Zeiss Microimaging GmbH, Germany) and subjected to UV and a 
subsequent dehydration process including repeated ethanol washings. PixCell II LCM System 
(Arcturus, Plaisir, France) was used to isolate glandular epithelial cells and stromal cells from 
the endometrium. Microdissected cells were collected on optically transparent LCM Macro 
caps and stored in -70°C until RNA isolation.  
3.7.2 mRNA microarray analysis 
The Whole Human Genome Oligo Microarray (Agilent Technologies, CA, USA) was used to 
perform microarray analysis. First strand cDNA was transcribed from 300 ng of total RNA 
using T7-Olige(dT) promoter primer. Samples were transcribed in vitro and Cy-3-labelled by 
using a Quick-AMP labelling kit (Agilent Technologies). cRNA was further fragmented into 
pieces ranging from 35 to 200 bases in size, and approved using Agilent 2100 Bioanalyzer 
technology. Fragmented cRNA samples were hybridized onto chips by means of 17 hours of 
incubation at 65°C with constant rotation, followed by a two-step microarray wash of one 
minute in two washing buffers (Agilent Technologies). Hybridized microarrays were scanned 
in an Axon 4100A scanner (Molecular Devices, Sunnyvale, CA, USA). 
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3.7.3 Data Analysis 
 Preprocessing and quality assessment 3.7.3.1
The gene level signals were extracted from CEL files by using Affymetix Expression 
ConsoleTM 1.3v software using Probe Logarithmic Intensity Error Estimation (PLIER) 
summarization algorithm. The normalization was performed by the Global Median method. 
In the initial step, the raw data was checked for any significant outliers. Any sample having 
more than three times the standard deviation was considered an outlier. The quality 
assessment of the raw data and filtered data was assessed by MA plots, Density plots, 
Hierarchical clustering, Quantile-Quantile plots, and Principal Component Analysis (PCA) 
plots. 
 Data filtering and differential expression analysis 3.7.3.2
Data filtering of PLIER data was performed by using a gene filter package in R 3.1.2v 
(Therneau and Ballman, 2008). A non-specific filter was applied with a hybridization signal  
≥ 40, yielding a total of 2625 genes in the stromal compartment and 3548 genes in the 
epithelial compartment.  
To analyse the differential expression, Linear Models for Microarray (LIMMA) and 
Significance Analysis of Microarrays (SAM) analysis were performed by using one 
ChannelGUI package in R software  (R Core Team, 2012). The data was log2 transformed 
for the differential analysis.  
3.7.4 Statistical analysis 
An unpaired t-test was performed to compare differences in the groups. A P-value less than 
0.05 was considered significant and a minimal change of 1.5-fold was applied to select up-
regulated and down-regulated genes. 
 
4 RESULTS AND DISCUSSION 
4.1 STUDY 1 
It is well known that up to 90% of women experience some degree of retrograde 
menstruation, but only 10-15 % of women develop endometriosis. To establish endometrial 
implants in ectopic sites, many factors are involved such as altered peritoneal environment, 
genetic factors, and reduced immune surveillance, together with an increased angiogenesis 
property and an enhanced capacity in adhesion and attachment of the shed endometrial cells.  
Endometrial cells with phenotypes relevant to stemness, attachment, adhesion, and migration 
can reach the peritoneal cavity with retrograde menstruation and are able to adhere and 
establish endometriotic implants/lesions. 
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In this paper, we have investigated the expression of a set of molecules with a possible 
involvement of adhesion, attachment, and invasion of endometrial cells: apoprotein E 
(ApoE), integrin-β-2 (ITGB2), laminin-y-1 (LAMC1), CD24 molecule, and junction 
adhesion molecule-1 (JAM-1).  
As shown in Fig 1 (Study I), endometrium from controls and women with endometriosis 
expressed ApoE, ITGB2, ITGB7, LAMC1, CD24, and JAM-1. Gene expression of ApoE and 
JAM-1 was decreased in both the proliferative and secretory phase in endometrium of women 
with endometriosis compared with the controls. Also, mRNA expression of LAMC1 was 
reduced in the endometrium from endometriosis patients compared with controls in the 
proliferative phase. An altered gene expression of CD24 was seen between the endometrium 
in endometriosis patients and endometriomas in the secretory phase. The ITGB2 protein 
expression was altered in epithelial cells between the endometrium from healthy volunteers 
and endometriosis patients in the secretory phase.  
The aetiology of endometriosis still remains debatable and the processes involved in the 
invasion mechanism of the endometrial cells are still poorly understood. Our study revealed 
for the first time an expression of ApoE, ITGB2, ITGB7, and LAMC1 in endometriomas and 
in eutopic endometrium. 
Collective cell migration is a phenomenon important in cancer biology (Friedl and Gilmour 
2009) and might play an important role in endometriosis development as well, even though 
the underlying concepts still have to be refined (Donnez et al., 2015). Traditionally, the 
molecules thought to facilitate cell-cell adhesion and cell-ECM adhesion in endometriosis 
have been members of the families of integrins, cadherins, laminin, and fibronectin (Béliard 
et al. 1997). 
The in vivo endometriotic invasion model developed by Kao et al. elucidates how ectopic 
endometrial mesenchymal stem cells clearly demonstrate a superior capacity for cell 
migration and invasion (Kao et al., 2011). 
In an experimental baboon model, more recently developed, molecules that have been 
nominated as crucial in the initial attachment/invasion include Ki-67, E-cadherin, and β-
catenin.  
How these and other molecules related to the initial establishment of ectopic endometrium are 
influenced by the oestrogen metabolites in the peritoneal fluid is, however, not reported so 
far. Studies focusing on this might contribute and complete the missing links.  
Our study showed an aberrant expression of CD24 in endometriosis patients where the 
cyclical appearance pattern was lacking compared to controls, a fact that could affect the 
endometrial receptivity recognized in this patient group (Brosens et al., 2012).  
Further, some of the genes explored in this study are also associated with malignancy. 
Elevated ApoE concentrations have been found in malignant ovarian cyst fluids, suggesting 
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an association with deregulated lipoprotein metabolism and ovarian cancer (Podzielinski et 
al., 2013). A dramatic up-regulation of the same protein has also been seen in poorly 
differentiated endometrial adenocarcinomas (Huvila et al., 2009), while a negative correlation 
can be observed with JAM-1 expression and endometrial cancer grade (Koshiba et al., 2009). 
CD24 has been associated with cancer progression and development and an enhanced 
expression has been seen in patients with endometrial carcinoma (Kim et al., 2009).  
There’s an urgent need to better understand the molecular linkage to malignant 
transformation in endometriosis to avoid unnecessary apprehension as well as potential 
overtreatment. This study contributes by providing new information on potential aetiological 
components as well as useful data on molecules correlated with malignant transformation. 
 
4.2 STUDY II 
The clinical expression of endometriosis varies significantly from patient to patient, 
suggesting that the nature of the pathology only partly depends on localization, duration, and 
the patient’s genetic predisposal. 
Accumulating evidence suggests that endometriosis is an epigenetic disease, which could 
explain the many features of the disorder and the difficulties in correlating the stage and 
clinical outcome in terms of pain and fertility-related aspects. The concept of an epigenetic 
disease opens up a broader understanding of the complexity of the disease mechanisms, but 
could also yield difficulty or confusion in diagnostic/therapeutic management of patients.  
In this paper, the epigenetic mechanism DNA-methylation of HOXA10 gene was analysed in 
different compartments of endometriosis as well as eutopic endometrium in cases and 
controls.  
The eutopic endometrium of women with endometriosis was significantly more methylated in 
comparison to controls (sequence 1: 8.68% in cases and 6.25% in controls: p=0.037, 
sequence 2: 11.89% in cases and 9.25% in controls: p=0.032). Eutopic endometrium was also 
significantly more methylated than ectopic tissue in the endometriosis patients (mean 
difference -3.6 sequence 1: p=0.001 and -6.0 sequence 2: p=0.0001). 
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Case 
Methylation 
ectopic 
tissue  
sequence 1 
(%) 
Methylation 
ectopic 
tissue 
sequence 2 
(%) 
Methylation 
endometrium 
sequence 1 
(%) 
Methylation 
endometrium  
sequence 2 
(%) 
1. Cyst 7 10 5 9 
2. Cyst 10 8 13 16 
3. Cyst 5 7 10 14 
4. Cyst 
Vaginal node 
5 
7 
6 
13 
17 16 
5. Cyst 
RVS 
3 
3 
6 
9 
7 15 
6. Muscle 6 10 8 16 
7. RVS 4 7 11 15 
8. Cyst 8 9 7 9 
9. RVS 3 4 15 18 
10. Cyst 4 5 11 13 
11. Peritoneal 
nodule 
5 6 11 13 
12. Peritoneal 
nodule 
4 4 6 7 
13. Cyst 5 5 11 11 
14. Cyst  6 2 6 7 
15. RVS                1 3 5 7 
16. Peritoneal 
Nodule 
4 5 5 8 
17. Cyst 
Peritoneal 
nodule 
5 
 
5 
3 
 
10 
5 8 
18. Cyst 5 6 4 11 
Table 1. Methylation (%) of the hoxa10 gene in eutopic and ectopic endometrium in 
endometriosis patients. 
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Figure 2. Chromatograms showing CpG island methylation (%) in eutopic endometrium and 
ectopic endometrium (cyst) in endometriosis patients (case nr 4) and eutopic endometrium of 
a healthy control. 
 
These results support the fact the endometrial function in endometriosis is altered and in this 
case negatively influencing the fertility capacity of the secretory phase. 
This study is the first to present data on endometrial HOXA10 methylation from different 
ectopic sites.  
Another aim of the study, besides investigating if the epigenetic mechanism of methylation 
was responsible for the aberrant expression of the gene previously described in endometriosis 
patients, was to explore whether an extra-ovarian involvement would correspond to a higher 
methylation status. It’s known that the disease stage is not correlated with the severity of pain 
and a correlation between a more severe stage of disease (extra-ovarian disease) and a higher 
extent of methylation could not be found. 
These results suggest that the eutopic endometrium represents the nucleus of the alteration, 
which is not then conserved and transferred in the ectopic atmosphere. In the literature, 
there’s a lack of data on the differences in molecular signature between ectopic and eutopic 
endometrium. Recently, a higher expression of HIF-1/2α, PAR-1/4, and VEGF-A has been 
described in ovarian endometriomas when compared to deep, infiltrating endometriosis 
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lesions (Filippi et al., 2015). This fact supports the idea that endometriosis is not just one 
disease but might be several diseases.  
The sample size of this study is restricted because it was not easy to find suitable subjects 
with endometriosis, as hormonal treatment prior to surgery was an exclusion criterion.     
Also, the fertility status was known for only 7 of the cases, as many hadn’t yet initiated an 
IVF itinerary or attempted pregnancy.  
An altered HOXA10 expression has also been associated with polycystic ovarian syndrome 
and hydrosalpinx (Du and Taylor 2015). For this study, these diseases didn’t represent an 
exclusion criterion and were not screened for. The women included in the study, cases as well 
as controls, had a regular menstrual cycle, which is presumably why cases of PCO were not 
included among the subjects. 
Our study reveals new and interesting data regarding the methylation of an important fertility-
regulating gene HOXA10 where we can find eutopic endometrium significantly more 
methylated in endometriosis patients, but with a non-correspondence between the stage of 
disease and methylation level of the ectopic endometrium.  
 
4.3 STUDY III 
Even though endometriosis-associated cancer (EAC) is a rare event, occurring in 0.7-2.5% of 
endometriosis patients, endometriosis is still considered a precursor of certain histological 
subtypes of ovarian cancer, such as ovarian endometrioid and clear cell ovarian carcinoma 
(Gadducci et al., 2014). The importance of a better understanding of the carcinogenic linkage 
with this common gynaecologic disorder is undebatable. In the context of stem cell origin of 
EAC, endometrial MSCs may undergo de-differentiation or reprogramming into endometrial 
cancer stem cells (CSCs) due to an altered microenvironment such as hypoxia and 
inflammation leading to tumour initiation (Ye et al.,2014).  
In this study, we aimed to investigate the molecular link between endometriotic and 
endometrial stem cells and the development of ovarian cancer by exploring CSC-specific 
markers, and its molecular signatures that were previously known with stem cell and cancer 
signalling, pluripotent functions, and asymmetric division. 
Selected populations positive for CD90, CD73, and CD105 (5-10%, endometrial stem cells) 
were characterized by higher expression of W5C5, EPCAM, CD44, and CD146. Differential 
potential was then assessed and a successful differentiation of MSCs into adipocytes, 
osteoblasts, and chondrocytes could be documented.  
The cell cycle analysis demonstrated a greater proliferative capacity and a reduced expression 
of apoptopic genes such as BCL-2 (p<0.05) (Fig. 2, Manuscript 2.) 
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Moreover, we could see that EndoSC exposed less proliferation potential compared with its 
paired eutopic sample, indicating a MSC niche alteration that could play a role in the onset 
mechanisms of endometriosis. 
RT-PCR assay could further outline an overexpression of genes involved in cancer 
metabolism, EMT, and re-programming (such as genes PTEN, MMP3, and TNF-α) when 
compared with the MSCs of patients and controls. Because the incidence of diverse genes did 
not reach significance, presumably explained by the high variability among the patients, a 
categorized univariate PCA and multivariate OPLS-DA modelling was used to investigate the 
biological importance of the molecular alterations and identify a subset of potentially ‘high-
risk’ samples in the P-EnSc and EndoSC groups. 
This characterization affirmed that the ‘low-risk’ subgroup presented a gene expression 
profile comparable to that of controls, while the ‘high-risk’ subgroup showed an expression 
pattern more similar to that seen in the positive controls (cancer cell line SKOV3).              
An up-regulation of genes involved in cancer metabolism, EMT, and re-programming could 
be distinguished (TP53, KRAS, TGF-alfa-1, SNAI1, SOX2, and NANOG), and TP53 turned 
out to be a master regulator behind the alterations found in the endometriosis patients (Fig. 3, 
Manuscript 3).  
The generation of 3D spheroids from sorted MSCs, identifying enrichment of pluripotent and 
self-renewal genes during comparison of sphere versus monolayer cultures, has generated 
significant data in our study. Spheroids from eutopic and ectopic endometrium showed a 
significant presence of CSC markers and pluripotent self-renewal genes compared with 
monolayer cultures. In particular, a distinction between ‘low-risk’/healthy groups and ‘high 
risk’ individuals was observed in relation to cells expressing SOX2, NANOG, CD44, and 
CD133. SOX2 has been recognized as responsible for reprogramming of MSCs into CSCs 
(Herreros-Villanueva et al., 2013), and a similar trend could be seen in our spheroid cultures.  
The analysis of CSC markers demonstrated in spheroids an increased expression compared to 
monolayer, and CD44+CD133+ and CD44+/CD133/ABCG2+ cells were significantly 
different between P-EnSC and EndoSC. Thus, we suggest that CD44/CD133 and/or ABCG2 
positive cell populations should be used to additionally recognise CSCs in endometriosis 
patients for further investigations in vivo. 
Tumour invasion assessment in a chemo-sensitivity assay in a 3D-tumour microenvironment 
revealed a MSC invasion in seven P-EnSC and six EndoSC out of the 11 paired samples, 
even though the difference in invasion potential was less marked between the endometriosis 
samples and the positive controls. This fact reminds us that we are studying a predominantly 
benign disease and not a clear premalignant condition. When further investigating the chemo-
sensitivity at an individual level through a viability assay, we could see in patient 36 a 
sensitivity for Paclitaxel in both P-EnSc and EndoSC, while Cisplatin sensitivity could be 
seen only in the endometrium sample (Fig. 7, Manuscript 3). 
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In this study, we identified a high-risk group of endometriosis patients that exhibited a 
significant up-regulation of some of the cancer stem cell markers and important genes 
involved in cancer metabolic pathway in their endometrial and endometriotic MSCs. 
However, further confirming studies that follow up such patients are necessary before we can 
categorize endometriosis patients as high or low risk for developing ovarian cancer based on 
the gene profile in the eutopic and ectopic endometrium. 
 
4.4 STUDY IV 
This study’s aim was to explore the gene expression profile of known cancer-correlated 
molecules in different endometrial compartments in order to better understand the potential 
links to malignant transformation of the eutopic endometrium in endometriosis patients. 
The following genes turned out to be significantly deregulated in the stromal compartment 
(Fig. 2, Manuscript 4): EHF (ΔΔCt -4.11; p=0.0001), PERP (ΔΔCt -3.16; P=0.005), JUN 
(ΔΔCt 4.24; p=0.012), WT1 (ΔΔCt 2.44; p=0.016), and in glands (Fig. 3, Manuscript 4): EZR 
(ΔΔCt 2.53; p=0.0001), SLPI (ΔΔCt -2.10; p=0.0002), PERP (ΔΔCt -2.11; p=0.002), and 
SLC34A2 (ΔΔCt -2.00; p=0.002). 
The impact of endometriosis on reproductive health and endometrial function is well known. 
The association with an increased risk of ovarian cancer is also well documented and the 
ovaries represent the far most common location for the malignant transformation.  
The literature has reported the eutopic endometrium as a rare transformation locus (Baba et 
al., 2016). On the other hand, the association between adenomyosis and endometrial cancer 
has been better established (Baba et al., 2016; Koike et al., 2013). Adenomyosis, as well as 
endometrial adenocarcinoma, is oestrogen-dependent and could possibly provide a model for 
better understanding of oestrogen-dependent malignant transformation.  
The reports on endometrial cancer in endometriosis patients have so far been conflicting and 
the carcinogenic linkage still remains poorly understood. Also, many epidemiological studies 
conducted on the association between endometriosis and endometrial cancer have had a 
limited sample size, which could explain why no significant correlation between the disorders 
has been found.  
In this study, we showed that several genes crucial in promoting endometrial tumourgenesis 
were significantly deregulated in the endometrium of endometriosis patients, namely EZR, 
SLPI, and EHF. EZR is known to be involved in the biology of cancer and plays a specific 
role in facilitating the indicators necessary for metastasis initiation. Also, SLP1 expression 
levels have been correlated with the malignant potential of cells (Devoogdt 2004) and a 
significant aberrant expression of these genes in the endometrium provides important 
information.  
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This study reveals important data inherent to the molecular linkage that could contribute to 
the malignant transformation of the endometrium in endometriosis.  
In the glandular compartment, the network between pathways involves cellular movement, 
cellular growth, and proliferation. Among the top canonical pathways in the stromal 
compartment is the TP53 signalling pathway, and among top diseases/bio functions, cancer 
occupies first place. The corresponding involvement in the glandular compartment is 
inflammatory disease and endocrine system disorders (Fig 1 a,b, Manuscript 4).  
This fact underscores the importance of observing the endometrial compartments separately, 
as their function and regulation can be markedly diverse. The samples in this study were all 
obtained on the same cycle day (LH+6-7), which is why a potential hormonal bias could be 
minimized.  
For future research, it would be particularly relevant to observe how these genes may 
demonstrate an altered expression in adenomyosis patients as well. This could enable 
identification of a subgroup of patients at risk of adenomyosis, which appears to be more 
strongly associated with endometrial cancer than endometriosis alone (Kok et al., 2015). 
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5 CONCLUSIONS AND FUTURE DIRECTIONS 
This thesis addresses the need for attention to the clinical impact of endometriosis, focusing 
on the involvement of endometrial stem cells in the development of EAC. Endometriosis is a 
multifactorial complex disease without a fully understood aetiology.  
We provided new information regarding pathogenesis, because for the first time, a set of 
molecules relevant to endometrial adhesion and attachment could be demonstrated in the 
endometrium of women with and without endometriosis (Study I).  
Our further molecular studies showed how endometrial mesenchymal stem cells, in a subset 
of patients, presented an up-regulation of cancer promoting genes such as PTEN, TP53, K-
ras, TGF-alfa-1, SNAI1, SOX2, and NANOG, and a down-regulation of the genes important 
for apoptosis, BCL-2. Based upon the biological significance of the deregulated genes, we 
could identify a subset of patients as high-risk. In this group, a MSC invasion was observed 
in a chemo-sensitivity assay in 3D-tumour microenvironment (Study III).                     
Confirmed across different molecular techniques, we believe that these findings contribute to 
a better understanding of the mechanisms involved in endometriosis-associated cancer and 
we now plan to carry out an in vivo study to further strengthen our results.  
Regarding the link to endometrial cancer development, we found in the global gene 
expression array 11 dis-regulated genes relevant for endometrial malignant transformation in 
both glands and the stromal compartment (Study IV). This is significant because available 
evidence of endometriosis-associated cancer is restricted and frequently contradictory mainly 
due to old studies with limited sample size. 
The molecular links responsible for malignant transformation in endometriosis patients are 
still not fully understood and we lack sufficient criteria to identify at-risk patients.                  
As endometriosis is a common disease and malignant transformation is rare, it’s extremely 
important to expand research in this field to avoid the risk of overtreatment.                     
Current knowledge does not provide any consensus on screening and risk-reducing 
prophylactic surgery. Therefore, efforts must be made to achieve better understanding of the 
molecular links to enable identification of patients according to their future risk of 
malignancy.  
We also showed for the first time how an epigenetic mechanism such as DNA-methylation is 
engaged in alternating the fertility-regulating gene HOXA10 gene in different types and stage 
of endometriosis (Study II). The field of epigenetics is expanding and more extensive surveys 
of epigenetic modifications in endometriosis are required to better categorize the epigenetic 
modification and the extent/type of endometriosis disease.  
Epigenetic knowledge could open up an attractive field of diagnostic tools and lead to novel 
therapeutic approaches as well as risk factor recognition. New epigenetic treatment 
approaches could also overcome the side effects and limits of current, short-term medical and 
surgical treatment strategies. 
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we now plan to carry out an in vivo study to further strengthen our results.  
Regarding the link to endometrial cancer development, we found in the global gene 
expression array 11 dis-regulated genes relevant for endometrial malignant transformation in 
both glands and the stromal compartment (Study IV). This is significant because available 
evidence of endometriosis-associated cancer is restricted and frequently contradictory mainly 
due to old studies with limited sample size. 
The molecular links responsible for malignant transformation in endometriosis patients are 
still not fully understood and we lack sufficient criteria to identify at-risk patients.                  
As endometriosis is a common disease and malignant transformation is rare, it’s extremely 
important to expand research in this field to avoid the risk of overtreatment.                     
Current knowledge does not provide any consensus on screening and risk-reducing 
prophylactic surgery. Therefore, efforts must be made to achieve better understanding of the 
molecular links to enable identification of patients according to their future risk of 
malignancy.  
We also showed for the first time how an epigenetic mechanism such as DNA-methylation is 
engaged in alternating the fertility-regulating gene HOXA10 gene in different types and stage 
of endometriosis (Study II). The field of epigenetics is expanding and more extensive surveys 
of epigenetic modifications in endometriosis are required to better categorize the epigenetic 
modification and the extent/type of endometriosis disease.  
Epigenetic knowledge could open up an attractive field of diagnostic tools and lead to novel 
therapeutic approaches as well as risk factor recognition. New epigenetic treatment 
approaches could also overcome the side effects and limits of current, short-term medical and 
surgical treatment strategies. 
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